Jenburkt Pharmaceuticals Ltd — Updates, 18-07-2025: Company Update

Jenburkt Pharmaceuticals concluded its 40th Annual General Meeting, held virtually. Shareholders approved the company's financial statements and a dividend of ₹18.00 per equity share for the financial year ended March 31, 2025. Key resolutions passed included the re-appointment of Shri Ashish U. Bhuta as a Director and as Chairman & Managing Director. The company also confirmed the appointment of Secretarial Auditors and ratified the Cost Auditor's remuneration. Management provided an overview of strong financial performance, strategic reorganisation of pharma divisions into NOVA and ZORA for focused brand portfolios, and efforts in innovation and AI.